---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-325856"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2025-12-19T23:59:59+00:00"
generated_at: "2026-05-16T12:31:00.874894+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BioMarin to acquire Amicus Therapeutics for $4.8B in all-cash deal at $14.50/share

## Summary
- BioMarin acquires Amicus for $14.50/share in cash, total equity value ~$4.8B; expected Q2 2026 close.
- Acquisition adds Galafold (Fabry) and Pombiliti+Opfolda (Pompe) products; Amicus's trailing 12-month revenue $599M.
- BioMarin secures up to $3.65B bridge loan from Morgan Stanley to fund transaction.
- Deal expected to be accretive to Non-GAAP diluted EPS in first 12 months post-close, substantially accretive from 2027.
- Amicus board unanimously recommends; subject to Amicus stockholder approval and regulatory clearances.

## SEC filing metadata
- accession: 0001193125-25-325856
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2025-12-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312525325856/0001193125-25-325856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312525325856/d49247d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-325856
- JSON: https://secwatch.observer/filing/0001193125-25-325856.json
- Plain text: https://secwatch.observer/filing/0001193125-25-325856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.